Bain Capital Life Sciences Investors, LLC
10% Owner · Kailera Therapeutics, Inc.
Every open-market stock purchase Bain Capital Life Sciences Investors, LLC has reported to the SEC on Form 4 that met our signal bar, parsed straight from the filings. This page tracks where those buys landed inside insider clusters and how the prices paid compare to where the stock trades now.
Where the buys stand today
- KLRA+45.6% vs price paidKailera Therapeutics, Inc.
One purchase totalling $25.0M at an average of $16.00 per share; the stock last traded at $23.30. See all insider buying in KLRA →
Avg price paid$16.00Latest price$23.30Market cap$3.0B - OLMA+121.7% vs price paidOlema Pharmaceuticals, Inc.
One purchase totalling $1.7M at an average of $5.76 per share; the stock last traded at $12.77. See all insider buying in OLMA →
Avg price paid$5.76Latest price$12.77Market cap$1.1B
Cluster participation
Qualifying buys grouped with other insiders buying the same stock — the pattern this site exists to catch.
All reported buys
Follow new qualifying clusters involving Bain Capital Life Sciences Investors, LLC or other insiders
Explore qualifying clusters from public SEC filings. Pro adds email and Telegram notifications after detection.
About this data
Figures are parsed from Bain Capital Life Sciences Investors, LLC's Form 4 filings on SEC EDGAR (CIK 1703031) and cover open-market purchases (transaction code P) — grants, option exercises, and sales are excluded, which is why totals here can differ from raw filing counts. Every row links to its source document.
This page is informational and reflects public filing data. It is not investment advice.